Epitra 250 Tablet contains Levetiracetam 250 mg, an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure activity. Epitra 250 is prescribed as monotherapy or adjunctive therapy in adults and pediatric patients aged one month and older. The tablet is to be taken orally, with or without food, as directed by a healthcare professional. Dosage adjustments may be necessary based on renal function and clinical response. Common adverse effects include dizziness, somnolence, headache, and fatigue, though the medication is generally well tolerated. Patients should be monitored for mood changes, behavioral symptoms, and signs of hypersensitivity. Epitra 250 should be used cautiously in patients with renal impairment, and abrupt discontinuation should be avoided to prevent seizure exacerbation. This medication is contraindicated in patients with known hypersensitivity to Levetiracetam or any of its components. Regular follow-up and adherence to prescribed dosing are essential to optimize therapeutic outcomes and minimize adverse effects.